This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medifast (MED) Q2 Earnings Top Estimates on OPTAVIA Strength
by Zacks Equity Research
Medifast's (MED) second-quarter 2020 results reflect solid earnings and sales. Strong OPTAVIA performance, thanks to a substantial rise in active earning coaches, boosted results.
Medifast (MED) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Medifast (MED) delivered earnings and revenue surprises of 6.52% and 12.97%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Here's How Inter Parfums (IPAR) Looks Ahead of Q2 Earnings
by Zacks Equity Research
Adverse impacts of coronavirus-induced temporary retail outlet closures are likely to get reflected in Inter Parfums' (IPAR) second-quarter 2020 performance.
Zacks.com featured highlights include: Medifast, USANA Health, UFP Industries, AllianceBernstein and Landstar System
by Zacks Equity Research
Zacks.com featured highlights include: Medifast, USANA Health, UFP Industries, AllianceBernstein and Landstar System
Top 7 Stocks Set to Beat on Earnings Today After Market
by Nalak Das
Seven top-ranked companies are poised to beat on earnings today after the closing bell.
What's in the Cards for Flowers Foods (FLO) in Q2 Earnings?
by Zacks Equity Research
Strength in branded retail with Nature's Own, Canyon Bakehouse, Dave's Killer Bread and Wonder brands might reflect on Flowers Foods' (FLO) Q2 results.
Things to Know Ahead of TreeHouse Foods (THS) Q2 Earnings
by Zacks Equity Research
TreeHouse Foods' (THS) second-quarter 2020 results are expected to reflect gains from increased demand and greater at-home consumption, offset by high costs and a soft Food Away From Home business.
6 Must-Buy Quality Stocks Screened on DuPont Analysis
by Sanghamitra Saha
Bet on six top-ranked stocks with higher ROE derived the DuPont way.
The Zacks Analyst Blog Highlights: Reynolds Consumer Products, Ollie's Bargain Outlet, Medifast and Flowers Foods
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Reynolds Consumer Products, Ollie's Bargain Outlet, Medifast and Flowers Foods
What's in the Cards for Medifast (MED) This Earnings Season?
by Zacks Equity Research
Strength in OPTAVIA brand is likely to get reflected in Medifast's (MED) second-quarter 2020 performance. However, rising SG&A expenses is a concern.
Has MEDIFAST INC (MED) Outpaced Other Consumer Staples Stocks This Year?
by Zacks Equity Research
Is (MED) Outperforming Other Consumer Staples Stocks This Year?
4 Essential Goods Stocks to Tap the Rise in Consumer Spending
by Ritujay Ghosh
The gradual easing of restrictions followed by the opening of the economy will boost spending which had hit rock bottom over the past few of months.
The Zacks Analyst Blog Highlights: BGS, MNST, MED, NUS and FLO
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BGS, MNST, MED, NUS and FLO
Here's How Beyond Meat (BYND) is Placed Ahead of Q2 Earnings
by Zacks Equity Research
Beyond Meat's (BYND) second-quarter results are likely to reflect strength in the retail business due to higher at-home consumption, while the foodservice business may remain under pressure.
What's in Store for Monster Beverage's (MNST) Q2 Earnings?
by Zacks Equity Research
Monster Beverage's (MNST) energy drink category is likely to have favorably impacted the company's second-quarter earnings results.
Top 5 Consumer Staple Stocks Ahead of Q2 Earnings Results
by Nalak Das
The consumer staples sector has so far reported relatively better results despite the decline of overall sector's earnings year over year.
Medifast (MED) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Medifast (MED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here Are the Factors Influencing Clorox's (CLX) Q4 Earnings
by Zacks Equity Research
Clorox's (CLX) Q4 performance is likely to have gained on increased demand for its products due to the coronavirus outbreak and cost-saving plans. However, currency woes and high costs are concerning.
Kellogg (K) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Kellogg (K) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Things to Note Ahead of Procter & Gamble's (PG) Q4 Earnings
by Zacks Equity Research
Strong demand for Procter & Gamble's (PG) products, which are deemed essential, is likely to have aided performance in fiscal fourth quarter.
The Zacks Analyst Blog Highlights: Turning Point Brands, Medifast, Emergent BioSolutions, Thermo Fisher Scientific and Sempra Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Turning Point Brands, Medifast, Emergent BioSolutions, Thermo Fisher Scientific and Sempra Energy
Jobless Claims Rise First Time Since March: 5 Defensive Picks
by Sreoshi Bera
The spike in unemployment claims and looming coronavirus fears have made markets volatile, making defensive picks lucrative investment options.
Looking for a Growth Stock? 3 Reasons Why Medifast (MED) is a Solid Choice
by Zacks Equity Research
Medifast (MED) possesses solid growth attributes, which could help it handily outperform the market.
Smucker Announces Dividend Hike: What Else Should You Know?
by Zacks Equity Research
Smucker (SJM) rewards shareholders by raising dividend for the 19th consecutive year.
Will Medifast Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor of Medifast